Mochi cuts compounded semaglutide to $60 and tirzepatide to $90

Mochi Health's advertised price for compounded semaglutide has fallen from $99/mo to $60/mo, and compounded tirzepatide from $199/mo to $90/mo — cuts of about 39% and about 55%. Archived captures of the company's homepage place the change between mid-July and the end of August 2026. Our own price database still carried the old figures, and this article corrects them.

What happened

Five captures of joinmochi.com in the Internet Archive show the old prices unchanged through the spring. The captures of March 3, April 14 and May 7 list "Compounded Semaglutide + $99/mo" and "Compounded Tirzepatide + $199/mo". The capture of May 15 renames the same two products "Compounded Injectable Semaglutide" and "Compounded Injectable Tirzepatide" and leaves both prices where they were, as does the capture of June 16.

The capture that shows the new prices is August 30. A banner across the top of that page reads: "New lower prices! Compounded Semaglutide starting at $99 $60 & Compounded Tirzepatide starting at $199 $90". In the page markup the $99 and the $199 both carry a line-through style; the $60 and the $90 do not. Further down, the product cards on the same capture read "Compounded Semaglutide — Starting at $60" and "Compounded Tirzepatide — Starting at $90". That capture also prices nine products the spring pages did not list, among them "Compounded Semaglutide Pill — Starting at $62" and "Compounded Orforglipron — Starting at $31".

A snapshot proves a price was live on the day it was taken. It does not date the change. The captures of July 13 and July 18 show a redesigned page whose product cards still read "Compounded Tirzepatide — Starting at $199" and "Compounded Semaglutide — Starting at $99". The June 18 capture, which sits between the June 16 and July 13 pages, renders the new layout with no product prices at all — an incomplete archive, not evidence that anything moved. So the cut is bracketed between July 18 and August 30, a window of about six weeks. Mochi lowered these prices between mid-July and the end of August. We cannot narrow it further and will not pretend otherwise.

The regulatory backdrop is worth recording. In an update dated April 1, 2026, the FDA reminded compounders of the conditions attached to the section 503A exemption, and stated that it "does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month." The same page notes that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list," and records that the period of enforcement discretion for 503A compounders ended in February 2025 for tirzepatide and in April 2025 for semaglutide. A cut this deep in compounded pricing while that restriction is in force is notable. Whether the two are connected we do not know, and Mochi has not said.

Why it matters

Start with our own error. Our database stores Mochi compounded semaglutide at $178/mo and compounded tirzepatide at $278/mo, last researched on August 17, 2026. Those numbers were assembled correctly — $99 medication plus the $79 membership, and $199 plus $79 — but on the old medication prices. The August research note even captured a "$60/mo" promotion in the fine print while the headline figure stayed at $178. Both stored figures are now roughly three times what Mochi advertises for the medication. They are wrong, and we are correcting them.

Then the arithmetic, because $60 on its own is not a monthly cost. Mochi's membership block on the August 30 capture reads "$79/mo", with the line "$39 due today for your first month" beneath it and the footnote: "$39 promotional rate available for new subscribers only. After the first month, monthly membership fee increases to $79/month. Promotional pricing not available in all states. Medications and diagnostic services not included in membership subscription." Add the two lines together and compounded semaglutide is about $99 in month one and about $139 a month after that. Compounded tirzepatide is about $129, then about $169.

$60 and $90 are the lowest advertised compounded semaglutide and tirzepatide medication prices among the brands we score, setting aside the reduced-strength microdose programs that Noom prices lower. On total monthly cost the ranking is closer. Ivim Health advertises compounded semaglutide at $75/mo and compounded tirzepatide at $133/mo on a six-month plan, and separately charges a $75/mo membership, so roughly $150 and $208 all in. Fridays prices compounded semaglutide at $150/mo on an annual prepay against $249 month to month, and shows $117/mo higher up the page once a discount code is applied — either side of Mochi's roughly $139. Our view is that the medication price is the headline and the membership decides the ranking. Competitor figures here were read on each brand's own pricing pages.

Our Mochi Health review carries the scorecard these prices feed into, and that score is under review now that its Value inputs have moved. The semaglutide cost guide and the tirzepatide cost guide set these figures against the rest of the market, the weight loss category page ranks the programs, and the true cost calculator exists for exactly this problem: putting medication, membership and every other recurring line into one monthly number before you sign up.

What this means for patients

• A lower advertised price is a price for new orders. If you are already a Mochi member, ask the company in writing whether the new medication price applies to your existing plan, and check what your next charge will be before it lands.
• Add the membership before you compare anything. The advertised figure is medication only; Mochi's own footnote says medications are not included in the membership subscription.
• The first month is promotional and the second is not. Budget for the step up from $39 to $79 on the membership line, and note that Mochi says the promotional rate is not available in all states.
• "Starting at" is the cheapest option on the page, not a flat rate. Confirm in writing what your own treatment will cost before you pay anything.
• Compounded products sit outside FDA approval. Mochi's own page states that "Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality." That is a regulatory fact about the category, not a judgement about any product.
• If you are shopping on price, compare all-in monthly cost across platforms rather than headline numbers. Our Mochi Health alternatives page lists the programs that compete with it. Nothing in this story is a reason to change your treatment; questions about your prescription go to your prescriber.